Raquel Nunes

Feasibility of Symptom Monitoring During the First Year of Endocrine Therapy for Early Breast Cancer Using Patient-Reported Outcomes Collected via Smartphone App

V. Stearns, J. Fetting, Elissa D. Thorner, 2023, JCO oncology practice.

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

E. Stringer-Reasor, S. Tolaney, C. Jochems, 2024, Nature communications.

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

E. Stringer-Reasor, S. Tolaney, C. Jochems, 2023, medRxiv.